Celyad Oncology S.A.
CYAD
Κατάταξη σε μετοχές
#31815
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Τιμή μετοχής
$0.23358713
Κεφαλαιοποίηση
$11.04M
Αλλαγή (1 ημέρα)
-7.56%
Αλλαγή (1 έτος)
-19.55%
Χώρα
BE
Εμπόριο Celyad Oncology S.A. (CYAD)
Κατηγορία
Healthcare
Ιστορικό τιμής μετοχής για την Celyad Oncology S.A. (CYAD)
Υψηλότερη τιμή κλεισίματος: $0.46 στις 2026-02-01
Χαμηλότερη τιμή κλεισίματος: $41.26 στις 2014-01-01
Χαμηλότερη τιμή κλεισίματος: $41.26 στις 2014-01-01
Ιστορικό τιμής μετοχής της Celyad Oncology S.A. από 2014 έως 2026
Ετήσια απόδοση τιμής μετοχής
| Έτος | Απόδοση |
|---|---|
| 2026 (TTM) | 43.07% |
| 2025 | -74.06% |
| 2024 | 103.77% |
| 2023 | -54.89% |
| 2022 | -79.56% |
| 2021 | -47.44% |
| 2020 | -26.01% |
| 2019 | -45.72% |
| 2018 | -47.31% |
| 2017 | 103.78% |
| 2016 | -60.19% |
| 2015 | 14.38% |
| 2014 | 0.00% |
Τιμή μετοχής για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Τιμή μετοχής | Μεταβολή 1Έτ% | Χώρα |
|---|---|---|---|
| $536.73 | 25.86% |
US
|
|
| $225.94 | 741.49% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.85 | 7.94% |
NL
|
